Skip to content
https://doi.org/10.3310/nihropenres.1115157.1
Document
NOT PEER REVIEWED
Download
metrics
VIEWS
253
 
downloads
167
CITE
How to cite this document:
National Institute for Health Research. The role of apixaban, aspirin and enoxaparin as thromboprophylaxis in patients newly diagnosed with multiple myeloma – an open label randomised feasibility study [version 1; not peer reviewed]. NIHR Open Res 2021, 1:16 (document) (https://doi.org/10.3310/nihropenres.1115157.1)
NOTE: it is important to ensure the information in square brackets after the title is included in this citation.
Award Final Report

The role of apixaban, aspirin and enoxaparin as thromboprophylaxis in patients newly diagnosed with multiple myeloma – an open label randomised feasibility study

National Institute for Health Research
  • Metrics
  • 253 Views
  • 167 Downloads
Published 16 Aug 2021

Award Final Report

The role of apixaban, aspirin and enoxaparin as thromboprophylaxis in patients newly diagnosed with multiple myeloma – an open label randomised feasibility study

[version 1; not peer reviewed]

National Institute for Health Research
Report
Award ID(s)
PB-PG-0214-3310
Competing Interests

The submitter of this document has been granted permission to upload the work on behalf of the Secretary of State for Health and Social Care.

Keywords
myeloma, thromboprophylaxis, venous thromboembolism, anticoagulants, low molecular weight heparin, aspirin, apixaban, direct oral anticoagulants
Comments
0 Comments
 

Are you an NIHR-funded researcher?

If you are a previous or current NIHR award holder, sign up for information about developments, publishing and publications from NIHR Open Research.

You must provide your first name
You must provide your last name
You must provide a valid email address
You must provide an institution.

Thank you!

We'll keep you updated on any major new updates to NIHR Open Research

Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.